Wacker Chemie Preliminary 2025 EBITDA Declines

Wacker Chemie reported preliminary 2025 EBITDA of about €430m, down 42% year-over-year (EBITDA excl. special effects ~€530m, down 29%), and preliminary EBIT of around -€180m; sales were ~€5.49bn, down 4%. Management attributed the declines to lower volumes and prices, reduced plant-utilization rates and negative currency effects, and foresees a 2025 net loss of about €800m after ~€600m of valuation adjustments. The company will publish its 2026 outlook with the annual report on March 11, 2026; the stock was trading at €71.70, down 2.8% at the last close.

Analysis

Market structure: Wacker’s print (EBITDA €430m, -42%; sales €5.49bn, -4%) signals industry-wide demand softness for silicones/polysilicon and lower utilization across divisions — buyers (downstream manufacturers) get pricing leverage, while diversified majors (BASF BAS.DE, Evonik EVK.DE, Covestro 1COV.DE) with broader product mixes and stronger balance sheets are positioned to take share. Expect margin compression to persist near-term: a ~30–40% EBITDA shock at Wacker typically forces spot pricing and contract concessions across the value chain, depressing supplier pricing power. Equity and credit will reprice; expect Wacker-equity vol + credit spreads widen 100–300bp; EUR may underperform if German industrial weakness persists.

Risk assessment: immediate tail risks include further valuation hits or covenant strains given a projected €800m net loss (including ~€600m write-downs) — a distressed refinancing scenario is low-probability but high-impact within 3–12 months. In the short term (days–weeks) the key catalysts are March 11 annual report and guidance; in months the driver is order intake and utilization recovery. Hidden dependencies: customer inventory destocking, energy/commodity (silicon, nat-gas) costs, and FX shifts (EUR weakness masks competitiveness) — monitor polysilicon spot and nat-gas spreads closely.

Trade implications: establish asymmetric shorts: prefer equity short (WCH.DE) sized 2–3% NAV or buy 3-month put spreads to limit premium — target 30–40% downside, stop 8–10% adverse move; implement a relative-value pair (short WCH.DE, long EVK.DE or BAS.DE) sized to neutralize beta for 3–6 months around March 11. Avoid outright Wacker IG bonds; if CDS liquidity exists, buy protection if spreads >250bps over Bunds as a cheap tail hedge. Rotate 1–3% into higher-quality specialty chemicals (EVK.DE) or industrial defensives while earnings normalize.

Contrarian angles: consensus may over-penalize one-off valuation adjustments — if Wacker’s March 11 report clarifies non-recurring items and 2026 EBITDA guidance improves to >€600m, the downside is partly priced in. A buying opportunity emerges if WCH.DE falls >25% from current levels on no-change operational guidance; consider buying 12-month LEAP calls sized 1–2% NAV as a recovery play. Historical parallels (cyclical chemical troughs 2019/2020) show sharp rebounds when utilization recovers and feedstock prices ease, so watch utilization breakeven (EBITDA margin >8%) as a re-entry signal.

Key Decisions for Investors

• Establish a 2–3% NAV short position in Wacker Chemie (WCH.DE) via stock or borrow within 2 weeks; set profit target of 30–40% downside and hard stop-loss at 8–10% adverse move. Hold at least through March 11, 2026 annual report or until guidance materially improves.
• Deploy a 1–2% NAV options hedge: buy 3-month WCH.DE put spreads (buy 5–10% OTM put, sell 20% OTM put) to capture downside into March 11 while capping premium outlay; close on IV spike or on report release.
• Initiate a 2% NAV relative-value pair: short WCH.DE and go long EVK.DE (Evonik) or BAS.DE (BASF) to neutralize market beta; rebalance to maintain delta neutrality and target 3–6 month horizon to capture share shift.
• Avoid new purchases of Wacker corporate bonds and consider buying CDS protection if spreads widen above 250 basis points over German Bunds; treat any CDS trade as a 6–12 month tail hedge sized 0.5–1% NAV.